VEEVA SYSTEMS INC - SaaS Valuation Profile VEEV

Veeva Systems Inc. is the leading provider of cloud-based software solutions for the global life sciences industry, serving pharmaceutical companies, biotechnology firms, contract research organizations, and medical device manufacturers. Founded in 2007 by Peter Gassner, a former Salesforce executive, and headquartered in Pleasanton, California, Veeva was built with the singular focus on becoming the technology backbone for life sciences organizations.

The company operates two primary product families. Veeva Commercial Cloud provides customer relationship management and commercial data solutions for pharmaceutical sales and marketing teams. Originally built on the Salesforce platform, Veeva CRM was the first cloud CRM tailored for pharma, enabling drug representatives to manage healthcare provider relationships, track samples and promotional activities, and access medical content while complying with industry regulations. Veeva is transitioning its CRM to Vault CRM, built on Veeva's own Vault Platform, eliminating dependency on Salesforce infrastructure.

Veeva Vault is the company's core technology platform, a unified cloud content management and data platform purpose-built for regulated industries. Vault applications span the entire drug development lifecycle: Vault Clinical (clinical data management, electronic trial master files, CTMS), Vault RIM (regulatory information management for global drug registrations), Vault Quality (quality management, training, and document control), Vault Safety (pharmacovigilance and adverse event reporting), and Vault Medical (medical affairs content and compliance). Each Vault application shares a common data model, workflow engine, and user interface, reducing integration complexity.

Veeva also provides master data solutions through its Network product (customer and product reference data) and Compass (patient and prescriber data), giving life sciences companies clean, compliant data for commercial operations and analytics.

The company targets life sciences organizations of all sizes, from emerging biotech startups to the world's largest pharmaceutical companies. Veeva's penetration of the top 20 pharma companies approaches 100%, and the company continues to expand by driving adoption of additional Vault applications within existing customers and capturing smaller biotech companies entering the market.

Veeva's revenue model combines subscriptions and professional services, with subscription revenue exceeding 80% of total revenue. The company generates approximately $2.5 billion in annual revenue with gross margins around 74% and operating margins near 40%, among the most profitable companies in enterprise SaaS. Net revenue retention is consistently above 115%.

Veeva made the unusual decision to convert to a Public Benefit Corporation in 2021, committing to balancing shareholder value with the interests of customers, employees, and the life sciences industry. This unique governance structure reinforces Veeva's long-term customer-first approach. With approximately 7,000 employees and deep regulatory expertise, Veeva has built an unassailable position as the dominant vertical SaaS platform in life sciences.